최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Diabetes & metabolism journal, v.36 no.4, 2012년, pp.262 - 267
Lee, Jinmi (Institute of Medical Research, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.) , Hong, Seok-Woo (Institute of Medical Research, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.) , Rhee, Eun-Jung (Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.) , Lee, Won-Young (Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.)
Non-alcoholic fatty liver disease (NAFLD), one of the most common liver diseases, is caused by the disruption of hepatic lipid homeostasis. It is associated with insulin resistance as seen in type 2 diabetes mellitus. Glucagon-like peptide-1 (GLP-1) is an incretin that increases insulin sensitivity ...
1 Ruhl CE Everhart JE Epidemiology of nonalcoholic fatty liver Clin Liver Dis 2004 8 501 519 15331060
2 Vanni E Bugianesi E Kotronen A De Minicis S Yki-Jarvinen H Svegliati-Baroni G From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010 42 320 330 20207596
3 Kim CH Younossi ZM Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome Cleve Clin J Med 2008 75 721 728 18939388
4 Kim W Egan JM The role of incretins in glucose homeostasis and diabetes treatment Pharmacol Rev 2008 60 470 512 19074620
5 MacDonald PE El-Kholy W Riedel MJ Salapatek AM Light PE Wheeler MB The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion Diabetes 2002 51 Suppl 3 S434 S442 12475787
6 Ahren B Schmitz O GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes Horm Metab Res 2004 36 867 876 15655721
7 Bourdel-Marchasson I Schweizer A Dejager S Incretin therapies in the management of elderly patients with type 2 diabetes mellitus Hosp Pract (Minneap) 2011 39 7 21 21441754
8 Ding X Saxena NK Lin S Gupta NA Anania FA Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice Hepatology 2006 43 173 181 16374859
9 Gupta NA Mells J Dunham RM Grakoui A Handy J Saxena NK Anania FA Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway Hepatology 2010 51 1584 1592 20225248
10 Sharma S Mells JE Fu PP Saxena NK Anania FA GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy PLoS One 2011 6 e25269 21957486
11 Adiels M Taskinen MR Boren J Fatty liver, insulin resistance, and dyslipidemia Curr Diab Rep 2008 8 60 64 18367000
12 Donnelly KL Smith CI Schwarzenberg SJ Jessurun J Boldt MD Parks EJ Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease J Clin Invest 2005 115 1343 1351 15864352
13 Liu Q Bengmark S Qu S The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD) Lipids Health Dis 2010 9 42 20426802
14 Reddy JK Rao MS Lipid metabolism and liver inflammation II Fatty liver disease and fatty acid oxidation Am J Physiol Gastrointest Liver Physiol 2006 290 G852 G858 16603729
15 Musso G Gambino R Cassader M Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD) Prog Lipid Res 2009 48 1 26 18824034
16 Pettinelli P Del Pozo T Araya J Rodrigo R Araya AV Smok G Csendes A Gutierrez L Rojas J Korn O Maluenda F Diaz JC Rencoret G Braghetto I Castillo J Poniachik J Videla LA Enhancement in liver SREBP-1c/PPAR-alpha ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion Biochim Biophys Acta 2009 1792 1080 1086 19733654
17 Shimomura I Bashmakov Y Horton JD Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus J Biol Chem 1999 274 30028 30032 10514488
18 Pratley RE The new science of GLP-1: effects beyond glucose control Johns Hopkins Adv Stud Med 2008 8 393 399
19 Lee J Hong SW Chae SW Kim DH Choi JH Bae JC Park SE Rhee EJ Park CY Oh KW Park SW Kim SW Lee WY Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice PLoS One 2012 7 e31394 22363635
20 Tushuizen ME Bunck MC Pouwels PJ van Waesberghe JH Diamant M Heine RJ Incretin mimetics as a novel therapeutic option for hepatic steatosis Liver Int 2006 26 1015 1017 16953843
21 Svegliati-Baroni G Saccomanno S Rychlicki C Agostinelli L De Minicis S Candelaresi C Faraci G Pacetti D Vivarelli M Nicolini D Garelli P Casini A Manco M Mingrone G Risaliti A Frega GN Benedetti A Gastaldelli A Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis Liver Int 2011 31 1285 1297 21745271
22 Lee YS Shin S Shigihara T Hahm E Liu MJ Han J Yoon JW Jun HS Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis Diabetes 2007 56 1671 1679 17369525
23 Tomas E Wood JA Stanojevic V Habener JF GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice Regul Pept 2011 169 43 48 21549160
24 Shirakawa J Fujii H Ohnuma K Sato K Ito Y Kaji M Sakamoto E Koganei M Sasaki H Nagashima Y Amo K Aoki K Morimoto C Takeda E Terauchi Y Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice Diabetes 2011 60 1246 1257 21330637
25 Bechmann LP Hannivoort RA Gerken G Hotamisligil GS Trauner M Canbay A The interaction of hepatic lipid and glucose metabolism in liver diseases J Hepatol 2012 56 952 964 22173168
26 Hettema EH Tabak HF Transport of fatty acids and metabolites across the peroxisomal membrane Biochim Biophys Acta 2000 1486 18 27 10856710
27 Minnich A Tian N Byan L Bilder G A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle Am J Physiol Endocrinol Metab 2001 280 E270 E279 11158930
28 Hashimoto T Fujita T Usuda N Cook W Qi C Peters JM Gonzalez FJ Yeldandi AV Rao MS Reddy JK Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype J Biol Chem 1999 274 19228 19236 10383430
29 Canto C Auwerx J PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure Curr Opin Lipidol 2009 20 98 105 19276888
30 Ruderman NB Xu XJ Nelson L Cacicedo JM Saha AK Lan F Ido Y AMPK and SIRT1: a long-standing partnership? Am J Physiol Endocrinol Metab 2010 298 E751 E760 20103737
31 Shen Z Liang X Rogers CQ Rideout D You M Involvement of adiponectin-SIRT1-AMPK signaling in the protective action of rosiglitazone against alcoholic fatty liver in mice Am J Physiol Gastrointest Liver Physiol 2010 298 G364 G374 20007851
32 Hou X Xu S Maitland-Toolan KA Sato K Jiang B Ido Y Lan F Walsh K Wierzbicki M Verbeuren TJ Cohen RA Zang M SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase J Biol Chem 2008 283 20015 20026 18482975
33 Canto C Gerhart-Hines Z Feige JN Lagouge M Noriega L Milne JC Elliott PJ Puigserver P Auwerx J AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity Nature 2009 458 1056 1060 19262508
34 Klonoff DC Buse JB Nielsen LL Guan X Bowlus CL Holcombe JH Wintle ME Maggs DG Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years Curr Med Res Opin 2008 24 275 286 18053320
35 Zheng D Ionut V Mooradian V Stefanovski D Bergman RN Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver Diabetes 2009 58 352 359 19011168
36 Park S Hong SM Ahn IS Exendin-4 and exercise improve hepatic glucose homeostasis by promoting insulin signaling in diabetic rats Metabolism 2010 59 123 133 19766272
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.